Subcutaneous immunotherapy injections work the same way as their intravenous counterparts — by changing or enhancing a person’s immune responses to cancer. Immunotherapy for cancer is a broad category ...

Monash University researchers, alongside key partner Halozyme Therapeutics, report findings in support of shifting the way ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. One subcutaneous injection of REGEN-COV — a combination ...

Tecentriq Hybreza, a subcutaneous delivery of the drug, was approved for certain types of sarcoma, in addition to lung, skin and liver cancers. The Food and Drug Administration (FDA) approved ...

PD-1 inhibitors belong to a class of medications known as immune checkpoint inhibitors, which have become an important part of many modern cancer treatment plans. PD-1 inhibitors work by helping the ...

KEYTRUDA QLEX is the first and only subcutaneously administered immune checkpoint inhibitor that can be given by a health care provider in as little as one minute “This approval is significant for ...

The combination of subcutaneous daratumumab with VRd was approved in July 2024 for induction and consolidation in patients ...

Keytruda Qlex is now FDA-approved for subcutaneous use in patients 12 and older with solid tumors, offering an alternative to IV administration. Subcutaneous administration can improve patient ...

The U.S. Food and Drug Administration has approved Leqembi Iqlik, a subcutaneous version of lecanemab, for weekly maintenance after the 18-month intravenous (IV) phase. Leqembi Iqlik is a subcutaneous ...

– Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on Ocrevus levels in the blood over 12 weeks – – Ocrevus subcutaneous injection was ...